Bergen, Norway

Monica Hellesoy

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Bergenbio Asa. Active years: 2021.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Monica Hellesoy: Innovator in Cancer Biomarkers

Introduction

Monica Hellesoy is a prominent inventor based in Bergen, Norway. She has made significant contributions to the field of cancer research, particularly in the area of biomarkers. Her work focuses on the detection and treatment of cancer, showcasing her dedication to advancing medical science.

Latest Patents

Monica Hellesoy holds a patent related to biomarkers for cancer. The patent, titled "The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject," outlines the use of PHGDH modulators to treat cancer. It also describes various methods for detecting EMT in a subject by measuring PHGDH expression and/or activity. This innovative approach has the potential to enhance cancer diagnostics and treatment options.

Career Highlights

Monica is associated with Bergenbio ASA, a company that focuses on developing innovative cancer therapies. Her work at the company has positioned her as a key player in the field of oncology. With her expertise, she continues to contribute to groundbreaking research that aims to improve patient outcomes.

Collaborations

Monica collaborates with notable colleagues, including Linn Nilsson and David Robert Micklem. These partnerships enhance her research efforts and foster a collaborative environment for innovation in cancer treatment.

Conclusion

Monica Hellesoy's contributions to cancer research through her patent on PHGDH as a biomarker exemplify her commitment to improving healthcare. Her work not only advances scientific knowledge but also holds promise for better cancer diagnostics and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…